Corcept Therapeutics CORT · NASDAQ
$110.16 -2.83% (-$3.21)
Summary
50 / 100 · Bulios Score
What speaks for it
- Revenue grew by 24% a year over the last 3 years.
- It holds more cash than debt: $111.0M against $9.42M.
- Out of every 100 USD of revenue, 13 USD is left as free cash.
What to watch
- The share price is above the Bulios Fair Price.
- It earns only 2.0 USD a year on every 100 USD of invested capital.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 223.2 USD for 1 USD of yearly profit. Over the last five years it was 32.5 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 17% a year over 5 years. Over the last 3 years it grew by 24% a year. Earnings per share fell by 2.0% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 1.7 USD
- Research and development 31 USD
- Sales and administration 67 USD
- Taxes and other -5.8 USD
- Net profit 6.6 USD
Net profit, industry median (Medical - Pharmaceuticals) 4.8 USD
Out of every 100 USD of revenue, 6.6 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 14
- Hold 9
- Sell 3
Today's price within the analysts' price targets
The average target of $125.33 is 14% above today's price. 54% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.